london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Switching to intravitreal aflibercept in poor responders to multiple bevacizumab for myopic choroidal neovascularization

Poster Details

First Author: T.Asai JAPAN

Co Author(s):    Y. Ikuno   K. Nishida               0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To describe the treatment response to aflibercept in patients with myopic choroidal neovascularization (mCNV) that showed insufficient or diminishing treatment effects under bevacizumab.

Setting:

2 case reports

Methods:

Two patients receiving intravitreal injections of aflibercept (IVA) after previous treatment with bevacizumab (IVB) between December 2009 and June 2014 were retrospectively reviewed. Clinical data such as best-corrected visual acuity (BCVA) or central subfield retinal thickness (CSRT) on optical coherence tomography (OCT) images were also collected.

Results:

Case 1; A seventy-seven year old female who had 8 times of IVB from December 2009 to October 2012. BCVA before the first IVB was 0.7, and after the last IVB was 0.4. BCVA improved from 0.1 before the first IVA to 0.5 after switching to aflibercept. CSRT had worsened from 227 μm 306 μm during IVB period, but reduced from 349 μm to 218 μm after switching to aflibercept. Case 2; A seventy-two-year-old female who had 9 times of IVB from December 2010 to October 2012. BCVA before the first IVB was 0.2, and maintained as 0.15 at the last IVB. BCVA changed from 0.15 before the first IVA to 0.2 after the last IVA. CSRT changed from 360 μm to 323 μm under during IVB, and from 353 μm to 253 μm after switching.

Conclusions:

Intravitreal aflibercept seems to be effective for patients with mCNV who were resistant to IVB.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy